Press Releases

CATO SMS Unveils New Brand

CATO SMS unveiled its new brand today, revealing an updated look and logo capturing the company’s powerful offering following the merger of CATO Research, LLC and Specialized Medical Services-oncology BV (SMS-oncology).

Biofourmis Closes $100 Million Series C Funding Round Led by SoftBank Vision Fund 2 to Accelerate U.S. and Global Expansion

Digital therapeutics leader Biofourmis closes $100 million Series C led by SoftBank. Funds will help accelerate virtual clinical trials business, among other initiatives.

Patient Groups Issue Guidelines for Ensuring Access to Care and Treatment for Rare Disease Patients, Citing Critical Needs and Gaps Further Exposed and Stretched During COVID-19

Global Genes and the Child Neurology Foundation, as part of the Rare Access to Critical Therapies (ACT) collaboration, announced today the joint release of a report highlighting and supporting guiding principles of rare disease care and access — which the groups assert are universally relevant to all patients with rare diseases.

Litmus Health Achieves HIPAA Compliance and NIST Cybersecurity Framework Adherence for Real World Data Infrastructure

Litmus Health, the research-ready infrastructure platform for real world data, that you might find interesting. As a bit of background, Litmus collects real world data from wearables and sensors, and analyzes these data for inclusion in clinical trials for their customers in pharma. This morning, the company announced that after a thorough third party security assessment, its infrastructure was determined to be secure and compliant when measured against federal security regulations.

APIS Assay Technologies Ltd expands bioinformatics expertise with acquisition of Beogenomics

Please see below for the latest news from APIS Assay Technologies Ltd announcing the acquisition of Beogenomics, a specialised software developer with major expertise in Bioinformatics and Artificial Intelligence (BIOX). Beogenomics develops both on-prem and secure cloud-based data analysis solutions — helping customers design, build and run custom tailored genomics & proteomics pipelines. The integration into Manchester-based APIS will support the launch of a new BIOX Service Line as part of the company’s ongoing Biomarker Research and Development activities.

ECCRT and IDDI establish partnership for continuous development of IDDI global team members

European Centre for Clinical Research Training (ECCRT) has been selected as a premium provider for continuous online learning by IDDI, a BIOSTATISTICAL AND ECLINICAL SERVICES provider for Pharmaceutical and Biotechnology companies. ECCRT will provide access to the eLearning ‘Virtual Campus’ platform that will allow IDDI’s global staff members to attend ICH Good Clinical Practice and related trainings.

WEP Clinical joins with Wren Healthcare to provide home healthcare services

WEP Group Holdings Limited (WEP), a specialist CRO focused on delivering lifesaving drugs to patients that have an unmet clinical need, is expanding its capabilities by making a strategic investment in Wren Healthcare Limited (Wren), a successful and growing clinical nursing healthcare provider in the EU.

CATO SMS ACQUIRES ARRAY BIOSTATISTICS

CATO SMS announced today that it has acquired Wilmington, NC-based Array Biostatistics (Array) to expand its offering of specialized clinical research solutions.

Matexcel Offers a Wide Selection of Natural Materials for Research Needs

Lifeasible Provides Virus-like Particles Production in Plant

Profacgen Provides Data Analysis Service for Biological Discovery

Huntington Study Group Announces a Partnership with Prilenia Therapeutics to Conduct a Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease

The Huntington Study Group (“HSG”), a world leader in clinical research for Huntington’s Disease (HD), announces a partnership with Prilenia Therapeutics, a clinical stage biotech company led by Michael R. Hayden, MD, PhD, to conduct PRidopidine Outcome On Function in Huntington’s Disease (PROOF-HD) clinical study. PROOF-HD is a global Phase 3, randomized, double-blind, placebo-controlled, parallel arm, multicenter study evaluating the efficacy and safety of pridopidine in patients with early stage HD.

Creative Peptides Provides Synthetic Peptides for Developing Vaccines

The Chemistry-Focused Technology Platform Is Optimized at Alfa Chemistry

Alfa Chemistry, the US-located chemical supplier, has recently announced that it has finished the optimization work of its chemistry-focused technology platform, which enables the company to offer a comprehensive range of services such as synthetic chemistry, chiral separations, small molecule synthesis, peptide, nucleoside, fluorinated building blocks, milligram preparation, kilogram GLP scale-up, reagent service, and compound management.

AI & Medicine Develops Medical Therapy and Research System to Facilitate Disease Treatment

AI & Medicine, one of the forerunners in the AI-assisted medicine area, announces that it has successfully developed a medical therapy and research system, which can assist in disease treatment, health management, adjuvant therapy, and deep mining of public document database.

Rho Experts Share Approach for Maximizing Benefits of Decentralized Trials During Free Webinar

Rho, a full-service contract research organization (CRO) with a proven track record of drug development success, will discuss its approach to and solutions for maximizing the benefits of decentralized clinical trials in an upcoming webinar, “CROs: The Tip of the Spear in Maximizing the Value of Hybrid, Virtual, and Synthetic Clinical Trials.” The webinar will take place on Wednesday, August 26, from 1-2 p.m. EST.

ERT and Science 37® Partner to Deliver High-Quality Data during Virtual Trials

Technology partnership enables trial sponsors to improve imaging, respiratory, and cardiac safety data quality while reducing patient burden and risk

Optogenetics Services Now Available at Profacgen

BOC Sciences Launched Its PROTACs Technology Platform to Assist Drug Development

Panthera further extends its network of clinical trial sites with the opening of a clinical trial site in North London in collaboration with Medicus Health Partners

Panthera’s network of UK clinical trials sites grows to seven with several others in development.